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Abstract
Dementia is a collective term for a number of neurodegenerative diseases 
characterized by cognitive impairment, memory loss, imparied judgement, 
and personality changes. There is currently no known cure and current 
treatment is focused mainly on symptomatic relief . Therefore, an 
intervention that can reduce the risk of dementia can have a major public 
health impact. This review aims to examine the current literature on 
cardiovascular health, specifically hyperlipidemia (HLD), and whether such a 
condition increases the risk of developing dementia in those ages 65 to 85. 
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Previously explored relationships between total cholesterol and cognitive 
health:
● apolipoprotein E (ApoE) and its association with LDL cholesterol and 
development of AD.
● Cholesterol’s role in production of β-amyloid peptide (Aβ).
● LDL and its effect on blood brain barrier permeability.
● LDL and HDL and carotid artery atherosclerosis.
This research hopes to clarify the relationship between HLD and subsequent 
cognitive decline through answering the following research question:
●  In the population of those at high risk for developing dementia (age 
65-85), does the cardiovascular risk factor of hyperlipidemia increase the 





➔ Performed in November 2019 using PubMed, ScienceDirect, and Google 
Scholar.
➔ Search Terms
◆ Coronary artery disease OR atherosclerosis OR hyperlipidemia OR 
cardiovascular health AND cognitive decline OR dementia OR Alzheimer’s 
disease.




● Relationships found were statistically significant (p<.05)
● Examination through various lenses
Limitations
● Examination through various lenses
● Lack of standardization among independent and dependent variable
● Small sample sizes
● Lack of blinding
● Inclusion of bias (selection, volunteer, recall, reporting, experimenter, and 
attrition)
● Timeline and Follow-up
Discussion 
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Overall,  the studies did not collectively find that lower cholesterol aids in prevention of 
cognitive decline. 
Given the limitations of the current meta-analysis, the evidence is insufficient to change 
current practice. However, some recommendations can be made. The study fosters support 
for taking early heart-healthy actions in the prevention and treatment of AD. It strengthens 
support for clinicians to serve as educators for their patients on the importance of 
monitoring their cholesterol.
The current research also paves the way for future studies that aim to delve deeper into the 
topic and further investigate ways to reduce the burden of disease on the aging population.
Important recommendations for future studies would be to:
➔ Include larger and more diverse samples and longer timeline and follow-up periods.
➔ Propose the research question among a more cohesive group of studies with more 
standardized variables. 
➔ Explore trends across various demographics, as such factors often play a role in the 
development and progression of various disease processes. 
Conclusion
1. Cox et al (2015): RCT examining the potential benefits of curcumin on cognitive 
functioning in an older adult population. This article was chosen because of curcumin’s 
potential to both improve cognitive function and lower cholesterol. Thus, findings from 
this study could shed light on the association between high cholesterol and reduced 
cognitive function.
2. Kivipelto et al (2002): Prospective population-based study of adults examining the 
relationship between the apolipoprotein E (apoE) allele, high serum total cholesterol, 
and high systolic blood pressure in midlife with the development of AD in late life. This 
article was chosen because it specifically included an examination of high cholesterol 
as a risk factor for Alzheimer’s disease (AD).
3. Simons et al (2002): RCT examining the potential neuroprotective effects of 
simvastatin in the brains of individuals with mild and moderate AD. This study was 
chosen because of its unique exploration of the relationship between cholesterol and 
development of AD.
4. Van Oijen et al (2007): Prospective cohort study examining the relationship between 
atherosclerosis and increased risk for dementia. This article was chosen because it 
specifically included an examination of atherosclerosis as a risk factor for Alzheimer’s 
disease (AD).
5. Vuletic et al (2006): RCT examining the impact of two different statins on AD brain 
pathology. This study adds to the literature on cholesterol levels and AD pathogenesis 
through its examination of the interrelationships between PLTP, apoE and statins in the 
brain.
6. Wardle et al (2000): RCT examining the effects of cholesterol-lowering diets on mood 
and cognitive function. This study adds to the existing literature through employment 
of an RCT design that facilitates a more thorough examination of the impact of 
cholesterol-lowering diets on mood and cognitive functioning. 
➔ Exclusion Criteria:
◆ Studies that involved individuals < 50 years.
◆ Studies in which the direct impact of 
atherosclerosis on cognitive decline could not 
be assessed due to the presence of multiple 
confounding risk factors among participants.
◆ Systematic review or meta-analyses. 
◆ Studies that involved clinical trials with 
animals.
➔ Inclusion Criteria:
◆ Written in 1999 or later.
◆ Published in a 
peer-reviewed journal.
◆ Written in English.
Results 
Table 1: Comparison of Study Designs















80mg/day x 4 
weeks 
Cognitive function (CMPAS), 
Mood (DASS, Chalder Fatigue 
Scale), blood sample for total 
cholesterol, LDL, HDL and AB 
Kivipelto M, 
Helkala E, 
Laakso M, et 
al.
Cohort 1449 65-79 21 years none N/A Serum total cholesterol (LB 
method), apoE allele (PCR), 










80mg/day x 26 
weeks
AB40 and AB42 (ELISA), 




spectrometry),  MMSE, AD 
Assessment Scale-Cognitive 
Portion
Van Oijen M, 
De Jong FJ, 
Witteman JC, 
et al. 
Cohort 6,647 55+ 7 years none N/A Carotid IMT and carotid plaques 
(B-mode ultrasonography), PAD 






RCT 24 “Adults” 3 months none  Pravastatin (80 
mg/day) x 3 
months or 
simvastatin (40 
mg/day) x 3 
months
Plasma apoE (Hitachi automated 
analyzer), 
CSF apoE (Dade Behring method), 
plasma and CSF PLTP (radio assay)
Wardle J, 
Rogers P, Judd 
P, et al.
RCT 176 Average 
age 55 






sessions x 12 
weeks
Cognitive function (battery of 
tests), GHQ, PSS, BDI, PMS 
subscale, STA inventory
Key: RCT: Randomized Control Trial, CMPAS: Computerized Mental Performance Assessment System including tasks such as immediate word recall, simple reaction time and rapid 
visual information processing, DASS: Depression, Anxiety and Stress Scales, LB method: Leibermann-Burchard method, DSMIV: Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, NINDS: National Institute of Neurological Disorders and Stroke criteria, ADRDA: Alzheimer’s Disease and Related Disorders Association criteria, ELISA: 
enzyme-linked immunosorbent assay, MMSE: Mini-Mental State Exam, IMT: carotid intima media thickness, GMSS: Geriatric Mental State Schedule, Battery of tests: Battery of 
computer tests assessing free-recall, tapping speed, reaction time and attention, GHQ: General Health Questionnaire, PSS: Perceived Stress Scale, BDI: Beck Depression Inventory, 
PMS subscale: Profile of Mood States depression and anger subscales, STA inventory: State-Trait Anger inventory.
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